miltefosine   Click here for help

GtoPdb Ligand ID: 11355

Synonyms: D-18506 | D18506 | Impavido® | Miltex® | n-hexadecylphosphorylcholine
Approved drug Immunopharmacology Ligand
miltefosine is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Miltefosine is an antiprotozoal (anthelmintic) drug that is primarily used to treat leishmaniasis. It has additional anticancer and immunomodulatory/anti-inflammatory activities [2]. The antitumour activity of miltefosine is principally mediated through the inhibition of Akt phosphorylation [4], which exerts a modulatory effect on the phosphatidylinositol 3-kinase (PI3K)-Akt/PKB cellular survival pathway.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 20
Topological polar surface area 68.4
Molecular weight 407.32
XLogP 6.63
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCCCCCCCCCCCOP(=O)(OCC[N+](C)(C)C)[O-]
Isomeric SMILES CCCCCCCCCCCCCCCCOP(=O)(OCC[N+](C)(C)C)[O-]
InChI InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
InChI Key PQLXHQMOHUQAKB-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Miltefosine is primarily used to treat leishmaniasis (oral administration), but may also be used topically to treat skin metastases in breast cancer [3,5]. In the EU this drug holds orphan designations as a treatment for visceral leishmaniasis, cutaneous T-cell lymphoma and Acanthamoeba keratitis.
External links Click here for help